Emergent BioSolutions Inc., a U.S.-based developer and manufacturer of vaccines and antibody therapies, launched its Singapore operations. The opening event included a ceremonial unveiling of EPIC Bio Pte Ltd that took place at Temasek Life Sciences Laboratory (TLL) in Singapore.

EPIC Bio is a recently formed Singapore-based joint venture with Temasek Life Sciences Ventures Pte Ltd (TLV), to develop, manufacture, and commercialize pandemic influenza vaccines and therapeutics.

"Emergent is pleased to enhance its presence in Asia-Pacific with initiatives that help carry out our corporate mission -- to protect life," said Fuad El-Hibri, Chairman and CEO of Emergent BioSolutions. "First, by broadening the scope of Emergent’s Singapore operations, not only will it continue to make our present and future biodefense products available, but it will also provide support to the company's ongoing tuberculosis program as well as explore manufacturing and business development opportunities in the region. Second, by forming EPIC Bio with TLV, Emergent leverages important technology and product development know how to complement TLL's research and development efforts in pandemic influenza."